Tag: HNSCC
-
Genmab’s Petosemtamab–Keytruda Combination Improves Survival in Phase 3 Head and Neck Cancer Trial
Genmab’s petosemtamab plus Keytruda improved survival in Phase 3 head and neck cancer testing. A closer look at the findings and their meaning for patients.